Abstract：
Pharmacotherapeutic care is now expanding in public mental health institutions. Annual grants are funding the public psychiatric field, hindering access to therapeutic innovation and expensive medications due to long length of stay. On the threshold of the French Healthcare & Social Services Ministry \"Ma Santé 2022\" plan (\"My Health 2022\"), there is a risk of altering the continuum of care because of the complexity of the financing of certain high added value therapies. Despite a desire to adapt the system to meet constantly changing health needs, no actions have been taken to this date in psychiatry, with no funds being allocated for valuable medication, in contrary to follow-up care and rehabilitation structures, to our knowledge. This reinforces the discrepancy with the evolution of research, and further widens the gap in inequalities between health sectors. Optimising the funding of expensive medicines in psychiatry would make it possible to reduce the stranglehold of current allocations. Following the example of recent reforms in the follow-up care and rehabilitation structures, extra funds for high value-added therapies would make it possible to reduce complex medical decisions: from prevention to reintegration, patient care continuity would be vastly guaranteed.
摘要：
药物治疗护理现在正在公共精神卫生机构中扩展。年度拨款资助公共精神病学领域，由于长期住院，阻碍了获得治疗创新和昂贵的药物。在法国医疗保健和社会服务部“马桑泰2022”计划（“我的健康2022”）的门槛上，由于某些高附加值疗法融资的复杂性,存在改变护理连续性的风险.尽管渴望适应系统以满足不断变化的健康需求，到目前为止，精神病学还没有采取任何行动，没有资金分配给有价值的药物，与后续护理和康复结构相反，我们的知识。这加强了与研究发展的差异，并进一步扩大了卫生部门之间的不平等差距。优化精神科昂贵药物的资金将有可能减少当前分配的束缚。以最近在后续护理和康复结构中进行的改革为例，用于高附加值疗法的额外资金将有可能减少复杂的医疗决定：从预防到重返社会，患者护理的连续性将得到极大的保证。
